Sherene Loi

List of Publications by Year in Descending Order

232 papers
30,946 citations
77 h-index
175 g-index
263 ext. papers
39,912 ext. citations
10.1 avg, IF
6.93 L-index

#	Paper	IF	Citations
232	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.. *Npj Breast Cancer*, **2022**, 8, 3	7.8	4
231	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.. *European Journal of Cancer*, **2022**, 164, 39-51	7.5	1
230	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. *Cancer Research*, **2022**, 82, P5-19-03-P5-19-03	10.1	
229	PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer.. *Science Advances*, **2022**, 8, eabk3338	14.3	0
228	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. *Journal of Clinical Oncology*, **2022**, JCO2101536	2.2	2
227	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. *European Journal of Cancer*, **2022**, 166, 219-228	7.5	0
226	Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2200284	2.2	
225	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 1-13	7.1	0
224	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.. *European Urology*, **2021**,	10.2	3
223	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. *Npj Breast Cancer*, **2021**, 7, 150	7.8	17
222	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. *Oncologist*, **2021**, 26, e749-e755	5.7	9
221	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. *Journal of the National Cancer Institute*, **2021**,	9.7	5
220	INPP4B promotes PI3K□dependent late endosome formation and Wnt/□catenin signaling in breast cancer. *Nature Communications*, **2021**, 12, 3140	17.4	6
219	The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.. *Journal of Clinical Oncology*, **2021**, 39, 1006-1006	2.2	8
218	Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. *Journal of the National Cancer Institute*, **2021**,	9.7	1
217	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. *Journal of the National Cancer Institute*, **2021**,	9.7	21
216	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. *Expert Opinion on Biological Therapy*, **2021**, 21, 945-962	5.4	4

215	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. *Cancer Discovery*, **2021**, 11, 2796-2811	24.4	10
214	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 309-317	9.7	19
213	Intratumoral heterogeneity in cancer progression and response to immunotherapy. *Nature Medicine*, **2021**, 27, 212-224	50.5	84
212	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. *Journal of the National Cancer Institute*, **2021**, 113, 1005-1016	9.7	56
211	Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer **2021**,		9
210	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. *Clinical Cancer Research*, **2021**, 27, 5607-5618	12.9	0
209	Extended adjuvant aromatase inhibitor therapy: less is more.. *Med*, **2021**, 2, 996-998	31.7	
208	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. *Breast Cancer Research and Treatment*, **2021**, 189, 599-606	4.4	5
207	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. *Breast*, **2021**, 59, 183-192	3.6	4
206	Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. *Breast Cancer Research*, **2021**, 23, 15	8.3	1
205	Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020. *Cancer Journal (Sudbury, Mass)*, **2021**, 27, 25-31	2.2	7
204	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. *Nature Communications*, **2020**, 11, 6335	17.4	15
203	Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer. *Cancer Cell*, **2020**, 37, 623-624	24.3	10
202	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *Npj Breast Cancer*, **2020**, 6, 15	7.8	8
201	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. *Npj Breast Cancer*, **2020**, 6, 16	7.8	47
200	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *Npj Breast Cancer*, **2020**, 6, 17	7.8	54
199	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. *Nature Medicine*, **2020**, 26, 1054-1062	50.5	74
198	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. *Lancet Oncology, The*, **2020**, 21, 519-530	21.7	159

197	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. *Journal of Pathology*, **2020**, 250, 667-684	9.4	83
196	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. *Nature Reviews Clinical Oncology*, **2020**, 17, 341-348	19.4	70
195	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. *Cancer Research*, **2020**, 80, 1304-1315	10.1	16
194	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. *Cancer Discovery*, **2020**, 10, 198-213	24.4	41
193	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death **2020**, 8,		233
192	Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 **2020**,		11
191	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) **2020**,		19
190	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. *Journal of Clinical Oncology*, **2020**, 38, 1000-1000	2.2	92
189	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. *PLoS Medicine*, **2020**, 17, e1003363	11.6	7
188	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. *Nature Cancer*, **2020**, 1, 546-561	15.4	37
187	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. *International Journal of Cancer*, **2020**, 147, 266-276	7.5	6
186	Metastatic Breast Cancer: TIL it is Too Late. *Clinical Cancer Research*, **2020**, 26, 526-528	12.9	3
185	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *New England Journal of Medicine*, **2020**, 382, 597-609	59.2	396
184	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 44-59	21.7	422
183	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. *Breast*, **2020**, 49, 55-62	3.6	25
182	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. *Lancet Oncology, The*, **2020**, 21, 1283-1295	21.7	62
181	Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol. *BMC Cancer*, **2020**, 20, 655	4.8	3
180	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet, The*, **2020**, 396, 1817-1828	40	306

179	Pervasive chromosomal instability and karyotype order in tumour evolution. *Nature*, **2020**, 587, 126-132	50.4	67
178	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. *Breast Cancer Research*, **2020**, 22, 91	8.3	12
177	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 5668-5681	12.9	17
176	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. *Clinical Cancer Research*, **2020**, 26, 354-363	12.9	19
175	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clinical Cancer Research*, **2020**, 26, 487-504	12.9	138
174	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. *Clinical Chemistry*, **2019**, 65, 1405-1413	5.5	31
173	Neoantigen-directed immune escape in lung cancer evolution. *Nature*, **2019**, 567, 479-485	50.4	358
172	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. *Clinical Cancer Research*, **2019**, 25, 3581-3588	12.9	36
171	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *Journal of Clinical Oncology*, **2019**, 37, 559-569	2.2	282
170	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. *Journal of Clinical Oncology*, **2019**, 37, 1169-1178	2.2	127
169	Molecular comparison of interval and screen-detected breast cancers. *Journal of Pathology*, **2019**, 248, 243-252	9.4	8
168	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncology, The*, **2019**, 20, 371-382	21.7	200
167	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 419-430	9.7	32
166	Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2 breast cancer metastasis. *Breast Cancer Research*, **2019**, 21, 94	8.3	41
165	Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. *Asia-Pacific Journal of Clinical Oncology*, **2019**, 15, 377-382	1.9	2
164	Triple-negative breast cancer: recent treatment advances. *F1000Research*, **2019**, 8,	3.6	69
163	Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain. *JACC: CardioOncology*, **2019**, 1, 298-301	3.8	9
162	Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. *Medicine and Science in Sports and Exercise*, **2019**, 51, 1573-1581	1.2	16

161	Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). *Breast*, **2019**, 48 Suppl 1, S44-S48	3.6	26
160	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. *Annals of Oncology*, **2019**, 30, 405-411	10.3	246
159	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. *Annals of Oncology*, **2019**, 30, 397-404	10.3	313
158	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. *Breast Cancer Research and Treatment*, **2019**, 174, 271-278	4.4	21
157	Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. *European Journal of Preventive Cardiology*, **2019**, 26, 305-315	3.9	53
156	Immune Infiltration in Invasive Lobular Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 768-776	9.7	55
155	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. *Nature*, **2018**, 554, 189-194	50.4	388
154	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 2804-2811	12.9	167
153	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Seminars in Cancer Biology*, **2018**, 52, 16-25	12.7	181
152	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. *Frontiers in Immunology*, **2018**, 9, 70	8.4	64
151	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. *Cancer Immunology Research*, **2018**, 6, 1069-1081	12.5	38
150	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 1335-1343	13.4	24
149	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e181564	13.4	8
148	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. *JCI Insight*, **2018**, 3,	9.9	68
147	Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).. *Journal of Clinical Oncology*, **2018**, 36, 1055-1055	2.2	3
146	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nature Medicine*, **2018**, 24, 986-993	50.5	420
145	Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. *Lancet Oncology, The* , **2018**, 19, 3-5	21.7	17
144	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. *Journal of Clinical Oncology*, **2018**, 36, 981-990	2.2	61

143	Fine-tuning chemotherapy in the era of dual HER2 targeting. *Lancet Oncology, The*, **2018**, 19, 1551-1554	21.7	1
142	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). *Science Signaling*, **2018**, 11,	8.8	32
141	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. *European Journal of Cancer*, **2018**, 104, 21-31	7.5	37
140	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. *PLoS ONE*, **2018**, 13, e0203346	3.7	2
139	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 2108-2121	59.2	1871
138	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 1926-1936	59.2	478
137	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. *Cancer Discovery*, **2018**, 8, 1390-1403	24.4	231
136	Checkpoint blockade in the treatment of breast cancer: current status and future directions. *British Journal of Cancer*, **2018**, 119, 4-11	8.7	55
135	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. *Cancer Research*, **2017**, 77, 1296-1309	10.1	46
134	Advancing Immunotherapy in Metastatic Breast Cancer. *Current Treatment Options in Oncology*, **2017**, 18, 35	5.4	12
133	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. *Science Translational Medicine*, **2017**, 9,	17.5	167
132	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. *Modern Pathology*, **2017**, 30, 952-963	9.8	37
131	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. *Lancet Oncology, The*, **2017**, 18, 52-62	21.7	164
130	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. *European Journal of Cancer*, **2017**, 72, 95-102	7.5	3
129	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. *Pathology*, **2017**, 49, 141-155	1.6	68
128	Combined CDK4/6 and PI3K nhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. *Cancer Research*, **2017**, 77, 6340-6352	10.1	99
127	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 527-537	11.2	29
126	Novel Targeted Agents and Immunotherapy in Breast Cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 65-75	7.1	5

125	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. *Cancer Immunology Research*, **2017**, 5, 871-884	12.5	41
124	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. *Cancer Research*, **2017**, 77, 5652-5663	10.1	64
123	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). *European Journal of Cancer*, **2017**, 85, 133-145	7.5	54
122	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. *Nature Communications*, **2017**, 8, 606	17.4	60
121	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Advances in Anatomic Pathology*, **2017**, 24, 311-335	5.1	299
120	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Advances in*	5.1	293
119	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. *Lancet Oncology, The*, **2017**, 18, 1009-1021	21.7	492
118	The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. *Npj Breast Cancer*, **2017**, 3, 23	7.8	5
117	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. *Oncologist*, **2017**, 22, 1028-1038	5.7	83
116	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). *Breast*, **2017**, 34 Suppl 1, S27-S30	3.6	64
115	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, 227-234	13.4	79
114	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. *JCO Precision Oncology*, **2017**, 1,	3.6	7
113	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. *Frontiers in Oncology*, **2017**, 7, 156	5.3	64
112	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. *Journal of Clinical Investigation*, **2017**, 127, 929-941	15.9	183
111	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. *Journal of Clinical Oncology*, **2017**, 35, 1008-1008	2.2	82
110	Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. *Journal of Clinical Oncology*, **2017**, 35, 1088-1088	2.2	47
109	Novel Targeted Agents and Immunotherapy in Breast Cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 65-75	7.1	6
108	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). *Oncologist*, **2016**, 21, 1165-1175	5.7	140

107	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 2961-8	2.2	420
106	Mouse Models of Tumor Immunotherapy. *Advances in Immunology*, **2016**, 130, 1-24	5.6	25
105	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 936-44	2.2	14
104	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. *Cancer Research*, **2016**, 76, 264-74	10.1	17
103	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nature Reviews Clinical Oncology*, **2016**, 13, 228-41	19.4	429
102	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. *Clinical Cancer Research*, **2016**, 22, 1499-509	12.9	311
101	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". *PLoS Medicine*, **2016**, 13, e1002204	11.6	81
100	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. *Oncotarget*, **2016**, 7, 67686-67698	3.3	36
99	Gene Expression Analysis: Applications **2016**, 137-149		
98	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. *Modern Pathology*, **2016**, 29, 1155-64	9.8	154
97	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. *Breast Cancer Research*, **2016**, 18, 121	8.3	73
96	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncology, The*, **2016**, 17, 425-439	21.7	931
95	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. *Cancer Research*, **2016**, 76, 4372-82	10.1	94
94	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. *Cancer Research*, **2016**, 76, 4236-48	10.1	25
93	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. *JAMA Oncology*, **2016**, 2, 1040-7	13.4	48
92	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. *Breast Cancer Research*, **2016**, 18, 43	8.3	67
91	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. *Annals of Oncology*, **2016**, 27, 1860-6	10.3	40
90	A community-based model of rapid autopsy in end-stage cancer patients. *Nature Biotechnology*, **2016**, 34, 1010-1014	44.5	46

89	The genomic landscape of breast cancer and its interaction with host immunity. *Breast*, **2016**, 29, 241-50	3.6	130
88	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. *Asia-Pacific Journal of Clinical Oncology*, **2016**, 12 Suppl 1, 3-18	1.9	5
87	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. *Current Breast Cancer Reports*, **2015**, 7, 59-70	0.8	1
86	The adverse mental health of carers: Does the patient diagnosis play a role?. *Maturitas*, **2015**, 82, 134-8	5	9
85	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. *Breast Cancer Research and Treatment*, **2015**, 152, 95-117	4.4	25
84	Precision medicine for metastatic breast cancer--limitations and solutions. *Nature Reviews Clinical Oncology*, **2015**, 12, 693-704	19.4	201
83	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. *Breast*, **2015**, 24, 290-3	3.6	18
82	RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. *Breast Cancer Research*, **2015**, 17, 24	8.3	109
81	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. *JAMA Oncology*, **2015**, 1, 448-54	13.4	359
80	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. *BMC Medicine*, **2015**, 13, 177	11.4	35
79	Relevance of tumor-infiltrating lymphocytes in breast cancer. *BMC Medicine*, **2015**, 13, 202	11.4	131
78	CD73: A potential biomarker for anti-PD-1 therapy. *OncoImmunology*, **2015**, 4, e1046675	7.2	23
77	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Annals of Oncology*, **2015**, 26, 259-71	10.3	1372
76	Uncovering the genomic heterogeneity of multifocal breast cancer. *Journal of Pathology*, **2015**, 236, 457-66	5.4	61
75	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *New England Journal of Medicine*, **2015**, 373, 209-19	59.2	940
74	Immunology and Immunotherapy of Breast Cancer **2015**, 457-470		
73	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *Journal of Clinical Oncology*, **2015**, 33, 983-91	2.2	650
72	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. *Cancer Immunology Research*, **2015**, 3, 506-17	12.5	198

71	Reply to A. Ocaña et al and P.G. Tsoutsou et al. *Journal of Clinical Oncology*, **2015**, 33, 1299-300	2.2	
70	Molecular segmentation of luminal breast: Reality in 2015?. *Breast*, **2015**, 24 Suppl 2, S41-3	3.6	
69	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 1334-9	2.2	164
68	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. *Journal of Clinical Oncology*, **2015**, 33, 511-511	2.2	4
67	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. *Journal of Clinical Oncology*, **2015**, 33, 516-516	2.2	5
66	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC).. *Journal of Clinical Oncology*, **2015**, 33, 613-613	2.2	1
65	PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.. *Journal of Clinical Oncology*, **2015**, 33, LBA502-LBA502	2.2	10
64	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. *Oncotarget*, **2015**, 6, 30306-16	3.3	11
63	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. *Journal of Clinical Oncology*, **2014**, 32, 3212-20	2.2	189
62	Biology of breast cancer during pregnancy using genomic profiling. *Endocrine-Related Cancer*, **2014**, 21, 545-54	5.7	48
61	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. *Breast*, **2014**, 23, 473-81	3.6	10
60	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Annals of Oncology*, **2014**, 25, 1544-50	10.3	780
59	Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691	7.2	524
58	Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. *Current Opinion in Oncology*, **2014**, 26, 562-7	4.2	13
57	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. *Genome Biology*, **2014**, 15, 470	18.3	9
56	PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. *Breast Cancer Research*, **2014**, 16, 201	8.3	75
55	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. *Journal of Clinical Oncology*, **2014**, 32, 510-510	2.2	3
54	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, TPS1134-TPS1134	2.2	1

53	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. *Journal of Clinical Oncology*, **2014**, 32, 630-630	2.2	
52	Evaluation of PI3K-pathway activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.. *Journal of Clinical Oncology*, **2014**, 32, 11060-11060	2.2	
51	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *Journal of Clinical Oncology*, **2013**, 31, 860-7	2.2	1023
50	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 11091-6	11.5	303
49	Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clinical Cancer Research*, **2013**, 19, 28-33	12.9	147
48	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. *Cancer Treatment Reviews*, **2013**, 39, 935-46	14.4	259
47	Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. *Molecular Endocrinology*, **2013**, 27, 350-65		73
46	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. *Journal of Clinical Oncology*, **2013**, 31, 1954-60	2.2	28
45	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. *Journal of the National Cancer Institute*, **2013**, 105, 960-7	9.7	112
44	Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. *OncoImmunology*, **2013**, 2, e24720	7.2	79
43	CD4+ follicular helper T cell infiltration predicts breast cancer survival. *Journal of Clinical Investigation*, **2013**, 123, 2873-92	15.9	554
42	PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. *PLoS ONE*, **2013**, 8, e53292	3.7	64
41	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, 11061-11061	2.2	
40	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. *Lancet Oncology, The*, **2012**, 13, e240-8	21.7	51
39	Dissecting the heterogeneity of triple-negative breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 1879-87	2.2	304
38	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. *Nature Medicine*, **2012**, 18, 1224-31	50.5	322
37	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. *Current Opinion in Oncology*, **2012**, 24, 623-34	4.2	38
36	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. *Clinical Cancer Research*, **2012**, 18, 1341-51	12.9	239

35	A three-gene model to robustly identify breast cancer molecular subtypes. *Journal of the National Cancer Institute*, **2012**, 104, 311-25	9.7	218
34	Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. *Clinical Cancer Research*, **2012**, 18, 1004-14	12.9	39
33	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. *Journal of Clinical Oncology*, **2012**, 30, 1996-2004	2.2	167
32	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. *Breast Care*, **2012**, 7, 267-72	2.4	11
31	Conference Scene: Advances in breast cancer translational research. *Breast Cancer Management*, **2012**, 1, 197-199	0.7	
30	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. *Lancet Oncology, The*, **2011**, 12, 1162-8	21.7	15
29	HER2-overexpressing breast cancer: time for the cure with less chemotherapy?. *Current Opinion in Oncology*, **2011**, 23, 547-58	4.2	15
28	Beyond trastuzumab: new treatment options for HER2-positive breast cancer. *Breast*, **2011**, 20 Suppl 3, S20-7	3.6	46
27	Gene profiling assay and application: the predictive role in primary therapy. *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 124-7	4.8	8
26	Time to move forward from "first-generation" prognostic gene signatures in early breast cancer. *Breast Cancer Research and Treatment*, **2011**, 128, 643-5	4.4	1
25	Identification of novel Ras-cooperating oncogenes in Drosophila melanogaster: a RhoGEF/Rho-family/JNK pathway is a central driver of tumorigenesis. *Genetics*, **2011**, 188, 105-25	4	65
24	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. *Endocrine-Related Cancer*, **2011**, 18, 721-30	5.7	6
23	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7142-7	11.5	334
22	Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. *Cancer Research*, **2011**, 71, 4809-20	10.1	239
21	Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. *OncoTargets and Therapy*, **2010**, 4, 1-11	4.4	22
20	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 10208-13	11.5	293
19	Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. *BMC Bioinformatics*, **2010**, 11, 277	3.6	64
18	Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. *BMC Medical Genomics*, **2009**, 2, 37	3.7	39

17	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. *BMC Genomics*, **2008**, 9, 239	4.5	272
16	Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?. *European Journal of Cancer*, **2008**, 44, 2813-8	7.5	17
15	Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. *PLoS ONE*, **2008**, 3, e2987	3.7	77
14	Clinical application of the 70-gene profile: the MINDACT trial. *Journal of Clinical Oncology*, **2008**, 26, 729-35	2.2	396
13	The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. *Critical Reviews in Oncology/Hematology*, **2007**, 61, 187-94	7	37
12	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. *Journal of Clinical Oncology*, **2007**, 25, 1239-46	2.2	650
11	Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. *Clinical Cancer Research*, **2007**, 13, 3207-14	12.9	759
10	Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. *Journal of Heart and Lung Transplantation*, **2007**, 26, 845-9	5.8	85
9	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *Journal of the National Cancer Institute*, **2006**, 98, 1183-92	9.7	976
8	Molecular forecasting of breast cancer: time to move forward with clinical testing. *Journal of Clinical Oncology*, **2006**, 24, 721-2; author reply 722-3	2.2	16
7	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. *Nature Clinical Practice Oncology*, **2006**, 3, 540-51		202
6	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. *Journal of the National Cancer Institute*, **2006**, 98, 262-72	9.7	1485
5	Breast cancer gene expression profiling: clinical trial and practice implications. *Pharmacogenomics*, **2005**, 6, 49-58	2.6	10
4	Obesity and outcomes in premenopausal and postmenopausal breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1686-91	4	253
3	Glomerulosclerosis: a paraneoplastic phenomenon?. *Nephrology*, **2004**, 9, 387-91	2.2	12
2	A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy. *Cancer Chemotherapy and Pharmacology*, **2004**, 54, 407-14	3.5	5
1	Challenges in breast cancer clinical trial design in the postgenomic era. *Current Opinion in Oncology*, **2004**, 16, 536-41	4.2	13